Oral azithromycin in extended dosage schedule for chronic, subclinical Chlamydia pneumoniae infection causing coronary artery disease: a probable cure in sight? Results of a controlled preliminary trial.

Int J Gen Med · 2012 · PMC3396117 · PMID 22807637

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The WIZARD (Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders) study failed to find a long-term benefit, even though a favorable trend was noted during and shortly after 3 months of azithromycin treatment. 12 More recent trials, ACES (Azithromycin and Coronary Events Study) 13 and PROVE IT-TIMI 22 (Pravastatin Or Atorvastatin Evaluation and Infection Therapy), 14 also reported a negative outcome.

also in 1,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.